MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.

Item
http://www.wikidata.org/entity/Q34227693
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical ApplicationsMinimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Prognostic significance of diagnosed WT1 level in acute myeloid leukemia: a meta-analysis.IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia.Guidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015.Biological and clinical consequences of NPM1 mutations in AML.The Transcriptome Study of Subtype M2 Acute Myeloblastic Leukemia.Copy-number analysis identified new prognostic marker in acute myeloid leukemia.Minimal/measurable residual disease in AML: consensus document from ELN MRD Working Party.Critical methodological factors in diagnosing minimal residual disease in hematological malignancies using quantitative PCR.
P2860

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin.

Item
http://www.wikidata.org/entity/Q34227693
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@ast
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@en
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@nl
type
label
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@ast
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@en
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@nl
prefLabel
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@ast
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@en
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
MRD assessed by WT1 and NPM1 t ...... nced by gemtuzumab ozogamicin.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P698
P932